The global neuropathic pain market size is evaluated at USD 7.97 billion in 2024, grew to USD 8.59 billion in 2025 and is projected to reach around USD 16.79 billion by 2034. The market is expanding at a solid CAGR of 7.73% between 2024 and 2034. The North America neuropathic pain market size is calculated at USD 3.99 billion in 2024 and is expected to grow at a CAGR of 7.74% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Neuropathic Pain Industry Impact
5.2. COVID-19 - Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Neuropathic Pain Market, by Drug Class, 2024-2034
8.1.1. Anticonvulsant
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Tricyclic Antidepressants
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Opioids
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Capsaicin
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Steroids
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2021-2034)
9.1. Neuropathic Pain Market, by Application, 2024-2034
9.1.1. Diabetic Neuropathy
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Spinal Stenosis
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Chemotherapy-Induced
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Peripheral Neuropathy
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2034)
10.1. Neuropathic Pain Market, by Route of Administration, 2024-2034
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Parenteral
10.1.2.1. Market Revenue and Forecast (2021-2034)
11.1. Neuropathic Pain Market, by Distribution Channel, 2024-2034
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.1.2. Market Revenue and Forecast, by Application (2021-2034)
12.1.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Application (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.2.2. Market Revenue and Forecast, by Application (2021-2034)
12.2.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Application (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Application (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Application (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.3.2. Market Revenue and Forecast, by Application (2021-2034)
12.3.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Application (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Application (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Application (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.4.2. Market Revenue and Forecast, by Application (2021-2034)
12.4.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Application (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Application (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Application (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Application (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.1. Nevro Corp. (U.S.)
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Lilly (U.S.)
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Astellas Pharma Inc. (Japan)
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Biogen (U.S.)
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Cirtec (U.S.)
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Integer Holdings Corporation (U.S.),
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. B. Braun SE (Germany)
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Medtronic (Ireland)
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Abbott (U.S.)
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Boston Scientific Corporation (U.S.)
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample